

## Akebia Therapeutics Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Nov-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

# ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 2 Clinical..... 11

    Discovery..... 14

[Return to Table of Contents](#)

# Akebia Therapeutics Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Akebia Therapeutics Inc
<b>Parent Company Name</b>	Akebia Therapeutics Inc
<b>Website</b>	http://akebia.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	2
<b>Number of Inactive Drugs</b>	3
<b>Number of Patents as Owner</b>	9
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	2
<b>Key Indications</b>	Cancer, Anemia, Ocular disease, Bacterial infection, Diabetes mellitus, Sepsis, Fungal infection, Hypertension, Peripheral vascular disease, Staphylococcus aureus infection, Viral infection, Wound healing
<b>Key Target-based Actions</b>	HIF prolyl hydroxylase inhibitor, HIF prolyl hydroxylase-2 inhibitor, Hypoxia inducible factor-1 stimulator, VEGF receptor agonist, HIF prolyl hydroxylase-1 inhibitor, Hypoxia inducible factor-2 alpha modulator, Hypoxia inducible factor-1 alpha modulator, Protein tyrosine phosphatase beta inhibitor, Hypoxia inducible factor-1 alpha inhibitor, Hypoxia inducible factor-1 beta modulator, VEGF receptor antagonist
<b>Key Technologies</b>	Small molecule therapeutic, Condensational synthesis, Drug combination, Nucleophilic substitutional synthesis, Ophthalmic formulation

## COMPANY PROFILE

### SUMMARY

Akebia Therapeutics Inc is a venture-backed start-up pharmaceutical company specializing in the development of products for ischemia and vascular disease.

### FINANCIAL

In November 2014, a personal stock purchasing plan was established in compliance with Section 10b5-1 of the Securities Exchange Act of 1934, to acquire shares of the company's common stock and the transactions under 10b5-1 purchasing plan would commence not earlier than December 15, 2014.

In June 2014, Akebia was added to the Russell 3000, Russell 2000 and Russell Global Indexes.

In February 2014, planned to conduct an IPO of its common stock and applied for listing of its common stock on the NASDAQ Stock Market under the ticker symbol 'AKBA'; in March 2014, the company initiated the pricing of its initial public offering of 5,882,353 shares of common stock at an offering price of \$17 per share. The company had also granted the underwriters a 30-day over-allotment option to buy up to an additional 879,647 shares at the initial public offering price. The trading of company's shares on the NASDAQ global market began under the ticker symbol "AKBA." The offering was expected to close on March 25, 2014; later that month, the company closed the public offering of 6,762,000 shares of common stock and raised net proceeds of approximately \$106.9 million.

In June 2013, Akebia completed a \$41 million series C financing.

In April 2011, the company closed a \$22 million series B preferred stock financing. At that time, the company raised \$14 million from the first closing, with the access to another \$8 million through the end of 2011. In January 2012, the company raised \$4.1 million from the closing of a tranche in series B financing.

In July 2009, Akebia raised \$12 million from the first closing of series A preferred stock financing round, and was to raise \$4 million from the second closing. By that time, the company had raised \$9 million from a prior round of the series A financing. In June 2010, the company raised \$5 million from the closing of its second tranche of series A financing (tranche was increased from \$4 million to \$5 million). A total of \$28 million was raised from all the rounds of series A financing.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	1	2	3
Neoplasm	1	0	1
Cardiovascular disease	0	1	1
Infectious disease	0	1	1
Hematological disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	1
No Development Reported	3

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	2	0	2

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Hematological disease	1	7
Genitourinary disease	0	2

[Return to Table of Contents](#)

## Trials by Phase

Phase	Ongoing	All
Phase 2	1	5
Phase 1	0	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	5	0	5
Endocrine disease	2	0	2
Gastrointestinal disease	5	0	5
Genitourinary disease	3	0	3
Hematological disease	6	0	6
Immune disorder	6	0	6
Musculoskeletal disease	5	0	5
Neoplasm	6	0	6
Ocular disease	4	0	4
Genetic disorder	1	0	1
Metabolic disorder	4	0	4
Neurological disease	4	0	4
Respiratory disease	2	0	2
Infectious disease	4	0	4
Injury	1	0	1
Inflammatory disease	4	0	4
Gynecology and obstetrics	1	0	1

[Return to Table of Contents](#)





Dermatological disease	4	0	4
------------------------	---	---	---

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### AKB-6548

#### AKB-6548 SNAPSHOT

<b>Drug Name</b>	AKB-6548
<b>Key Synonyms</b>	
<b>Originator Company</b>	Procter & Gamble Pharmaceuticals Inc
<b>Active Companies</b>	Akebia Therapeutics Inc
<b>Inactive Companies</b>	Procter & Gamble Pharmaceuticals Inc
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Anemia
<b>Target-based Actions</b>	Hypoxia inducible factor-2 alpha modulator;HIF prolyl hydroxylase inhibitor
<b>Other Actions</b>	Blood system agent;Hematopoietic stimulant;Erythropoietin release stimulator
<b>Technologies</b>	Oral formulation;Small molecule therapeutic
<b>Last Change Date</b>	17-Nov-2014

#### AKB-6548 DEVELOPMENT PROFILE

#### SUMMARY

Akebia Therapeutics, under license from Procter & Gamble Pharmaceuticals, is developing AKB-6548, the lead from a series of orally active small-molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors that stabilize HIF2 alpha, for the potential treatment of anemia and related disorders,. In July 2010, a phase II study began ; in October 2010, positive data were reported from the trial. In June 2011, a phase IIa study began ; in April 2012, the trial was completed and results were reported . In July 2013, a phase IIb trial for anemia with chronic kidney disease (CKD) was initiated and the study was expected to complete in November 2014; in October 2014, positive top-line results were reported. In September 2014, a phase II trial in patients with anemia related to CKD undergoing dialysis was initiated. At that time, data were expected in the third quarter of 2015. In October 2014, the company planned to initiate global phase III registration studies in 2015. In January 2012, the company was seeking to outlicense the drug for the initiation of phase III pivotal studies.

#### AKB-6548 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Akebia Therapeutics Inc	Anemia	US	Phase 2 Clinical	22-Jul-2010
Procter & Gamble Pharmaceuticals Inc	Anemia	US	Discontinued	17-Sep-2007

[Return to Table of Contents](#)



## AKB-6548 DRUG NAMES

Names	Type
HIF-PH inhibitors (anemia), Akebia	
hypoxia-inducible factor prolyl hydroxylase inhibitors (anemia), Akebia/Procter & Gamble	
AKB-6548	Research Code

## AKB-6548 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Anemia											
0	0	0	0	1	5	0	2	0	0	1	7
End stage renal disease											
0	0	0	0	0	2	0	0	0	0	0	2

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	5	0	3	0	0	1	8

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical



Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

AKB-6548 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
The Procter & Gamble Co	1	0	0	0	1
Akebia Therapeutics Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

## AKB-6899

### AKB-6899 SNAPSHOT

Drug Name	AKB-6899
Key Synonyms	
Originator Company	Akebia Therapeutics Inc
Active Companies	Akebia Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer;Ocular disease
Target-based Actions	HIF prolyl hydroxylase inhibitor;VEGF receptor agonist
Other Actions	Erythropoietin release stimulator;Anticancer
Technologies	Small molecule therapeutic
Last Change Date	06-May-2014

### AKB-6899 DEVELOPMENT PROFILE

#### SUMMARY

Akebia Therapeutics is investigating AKB-6899, a hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, for the potential treatment of cancer and ocular diseases. In May 2014, the drug was listed as being in preclinical development and at that time, the company planned filing an IND to initiate a phase I trials.

### AKB-6899 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Akebia Therapeutics Inc	Cancer	US	Discovery	05-May-2014
Akebia Therapeutics Inc	Ocular disease	US	Discovery	05-May-2014

### AKB-6899 DRUG NAMES

Names	Type
hypoxia inducible factor-prolyl hydroxylase inhibitor (cancer/ocular disease), Akebia	
AKB-6899	Research Code

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

